Capitulo1
Capitulo2
Capitulo3
Capitulo4
Capitulo5
Capitulo6
Capitulo7
Capitulo8
Capitulo2
Capitulo3
Capitulo11
Capitulo12
Capitulo13
Capitulo14
Capitulo15
Capitulo16
Capitulo17


1. Diabetes in America, edn 2. Edited by Harris M, Cowie C, Stern M, et al. Bethesda: National Institutes of Health; 1995.

2. Harris M, Flegal K, Cowie C, et al.: Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults.The Third National Health and Nutrition Examination Survey, 1988–1994. Diabetes Care 1998, 21:518–524.

3. Bogardus C, Lillioja S, Bennett P: Pathogenesis of NIDDM in Pima Indians. Diabetes Care 1991, 14:685–690.

4. Weyer C, Tataranni PA, Bogardus C, et al.: Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care 2000, 24:89–94.

5. Weyer C, Bogardus C, Mott D, et al.: The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999, 104:787–794.

6. Kahn S:The importance of b-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 2001, 86:4047–4058.

7. Pratley R,Weyer C:The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus. Diabetologia 2001, 44:929–945.

8. Hamman R: Genetic and environmental determinants of noninsulin-dependent diabetes mellitus (NIDDM). Diabetes Metab Rev 1992, 8:287–338.

9. Stefan N, Fritsche A, Haring H, et al.: Effect of experimental elevation of free fatty acids on insulin secretion and insulin sensitivity in healthy carriers of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 gene. Diabetes 2001, 50:1143–1148.

10. Horikawa Y, Oda N, Cox N, et al.: Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet 2000, 26:163–175.

11. Gloyn A:The genetics of diabetes: a progress report. Practical Diabetes Int 2001, 18:246–250.

12. Shaw J, Purdie D, Neil H, et al.: The relative risks of hyperglycemia, obesity and dyslipidemia in relatives of patients with type II diabetes mellitus. Diabetologia 1999, 42:24–27.

13. Shatten B, Smith G, Kuller L, et al.: Risk factors for the development of type 2 diabetes among men enrolled in the usual care group of the multiple risk factor intervention trial. Diabetes 1993, 16:1331–1338.

14. Gerich J,Van Haeften T: Insulin resistance versus impaired insulin secretion as the genetic basis for type 2 diabetes. Curr Opin Endo Diab 1998, 5:144–148.

15. Pimenta W, Kortytkowski M, Mitrakou A, et al.: Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM. JAMA 1995, 273:1855–1861.

16. Vaag A,Alford F, Beck-Nielsen H: Intracellular glucose and fat metabolism in identical twins discordant for non–insulin-dependent diabetes mellitus (NIDDM): acquired versus genetic metabolic defects. Diabetic Med 1996, 13:806–815.

17. Cerasi E, Luft R: Insulin response to glucose infusion in diabetic and nondiabetic monozygotic twin pairs: genetic control of insulin response. Acta Endocrinol 1967, 55:330–345.

18. Barnett A, Spiliopoulos A, Pyke D, et al.: Metabolic studies in unaffected co-twins of noninsulin-dependent diabetics. Br Med J 1981, 282:1656–1658.

19. Pyke D, Taylor K: Glucose tolerance and serum insulin in unaffected identical twins of diabetics. Br Med J 1967, 4:21–22.

20. Hu F, Manson J, Stampfer M, et al.: Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001, 345:790–797.

21. Choi B, Shi F: Risk factors for diabetes mellitus by age and sex: results of the national population health survey. Diabetologia 2001, 44:1221–1231.

22. Marshall J, Hoag S, Shetterly S, et al.: Dietary fat predicts conversion of impaired glucose tolerance to NIDDM. Diabetes Care 1994, 17:50–56.

23. Wei M, Schweitner H, Blair S:The association between physical activity,physical fitness and type 2 diabetes mellitus. Compr Ther 2000,26:176–182.

24. Wannamethee S, Shaper A, Perry I: Smoking as a modifiable risk factorfor type 2 diabetes in middle-aged men. Diabetes Care 2001,24:1590–1595.

25. Rich-Edwards J, Colditz G, Stampfer M, et al.: Birthweight and the riskfor type 2 diabetes mellitus in adult women. Ann Intern Med 1999,130:278–284.

26. Eriksson J, Lindstrom J,Tuomilehto J: Potential for prevention of type 2diabetes. Br Med Bull 2001, 60:183–199.

27. Knowler W, Barrett-Connor E, Fowler S, et al.: Reduction in the incidenceof type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393–403.

28. Tuomilehto J, Lindstrφm J, Eriksson J, et al.: Prevention of type 2 diabetesmellitus by changes in lifestyle among subjects with impaired glucosetolerance. N Engl J Med 2001, 344:1343–1350.

29. Pan XR, Li GW, Hu YH, et al.: Effects of diet and exercise in preventingNIDDM in people with impaired glucose tolerance:The Da Qing IGTand Diabetes Study. Diabetes Care 1997, 20:537–544.

30. Erikkson K, Lindgarde F: Prevention of type 2 (noninsulin-dependent)diabetes mellitus by diet and exercise. Diabetologia 1991, 34:891–898.

31. Porte D, Jr., Kahn S: Beta-cell dysfunction and failure in type 2 diabetes:potential mechanisms. Diabetes 2001, 50(Suppl 1):S160–S163.

32. Carey D, Jenkins A, Campbell L, et al.:Abdominal fat and insulin resistancein normal and overweight women: direct measurements reveal astrong relationship in subjects at both low and high risk of NIDDM.Diabetes 1996, 45:633–638.

33. Banerji M, Chaiken R, Gordon D, et al.: Does intra-abdominal adiposetissue in black men determine whether NIDDM is insulin-resistant orinsulin-sensitive? Diabetes 1995, 44:141–146.

34. Byrne M, Sturgis J, Sobel R, et al.: Elevated plasma glucose 2 h postchallengepredicts defects in beta-cell function. Am J Physiol 1996,270:E572–E579.

35. Nesher R, Casa Della L, Litvin Y, et al.: Insulin deficiency and insulin resistance in type II (noninsulin-dependent) diabetes: quantitative contributions of pancreatic and peripheral responses to glucose homeostasis. Eur J Clin Invest 1987, 17:266–274.

36. Campbell P, Mandarino L, Gerich J: Quantification of the relative impairmentin actions of insulin on hepatic glucose production and peripheralglucose uptake in non–insulin-dependent diabetes mellitus. Metabolism1988, 37:15–21.

37. Kalant N, Leibovici D, Fukushima N, et al.: Insulin responsiveness of superficial forearm tissues in type 2 (noninsulin-dependent) diabetes. Diabetologia 1982, 22:239–244.

38. Bonora E, Bonadonna R, DelPrato S, et al.: In vivo glucose metabolism in obese and type II diabetic subjects with or without hypertension. Diabetes 1993, 42:764–772.

39. Nosadini R, Solini A,Velussi M, et al.: Impaired insulin-induced glucose uptake by extrahepatic tissue is hallmark of NIDDM patients who have or will develop hypertension and microalbuminuria. Diabetes 1994, 43:491–499.

40. Groop L, Ekstrand A, Forsblom C, et al.: Insulin resistance, hypertensionand microalbuminuria in patients with type 2 (non–insulin-dependent)diabetes mellitus. Diabetologia 1993, 36:642–647.

41. Gerich J:The genetic basis of type 2 diabetes mellitus: Impaired insulin secretion versus impaired insulin sensitivity. Endocr Rev 1998, 19:491–503.

42. Dohm GL,Tapscott E, Pories W, et al.: An in vitro human muscle preparationsuitable for metabolic studies. Decreased insulin stimulation ofglucose transport in muscle from morbidly obese and diabetic subjects. J Clin Invest 1988, 82:486–494.

43. Boden G: Role of fatty acids in the pathogenesis of insulin resistance andNIDDM. Diabetes 1997, 46:3–10.

44. Hotamisligil G, Spiegelman B:Tumor necrosis factor-a: a key component of the obesity-diabetes link. Diabetes 1994, 43:1271–1278.

45. Steppan C, Bailey S, Bhat S, et al.:The hormone resistin links obesity to diabetes. Nature 2001, 409:307–312.

46. Ahima R, Flier J: Leptin. Annu Rev Physiol 2000, 62:413–437.

47. Ahima R, Flier J:Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000, 11:327–332.

48. Saltiel A, Kahn C: Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001, 414:799–806.

49. Kelley D, Goodposter B: Skeletal muscle triglyceride: an aspect ofregional adiposity and insulin resistance. Diabetes Care 2001, 24:933–941.

50. Virkamaki A, Korsheninnikova E, Seppala-Lindroos A, et al.:Intramyocellular lipid is associated with resistance to in vivo insulinactions on glucose uptake, antilipolysis, and early insulin signaling pathwaysin human skeletal muscle. Diabetes 2001, 50:2337–2343.

51. Mitrakou A, Kelley D,Veneman T, et al.: Contribution of abnormal muscle and liver glucose metabolism in postprandial hyperglycemia in noninsulin- dependent diabetes mellitus. Diabetes 1990, 39:1381–1390.

52. Dinneen S, Gerich J, Rizza R: Carbohydrate metabolism in noninsulindependent diabetes mellitus. N Engl J Med 1992, 327:707–713.

53. DCCT Research Group:The effect of intensive treatment of diabetes onthe development and progression of long-term complications in insulindependent diabetes mellitus. N Engl J Med 1993, 329:977–986.

54. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensiveblood-glucose control with metformin on complications in overweightpatients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854–865.

55. Reichard P, Pihl M, Rosenqvist U, et al.: Complications in IDDM arecaused by elevated blood glucose level:The Stockholm DiabetesIntervention Study (SDIS) at 10-year follow up. Diabetologia 1996,39:1483–1488.

56. Stratton I,Adler A, Neil HA, et al.:Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000, 321:405–412.

57. Gerstein H, Pais P, Pogue J, et al.: Relationship of glucose and insulin levels to the risk of myocardial infarction: a case-control study. J Am Coll Cardiol 1999, 33:612–619.

58. Khaw K-T,Wareham N, Luben R, et al.: Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). Br Med J 2001, 322:15–18.

59. Lebovitz H: Insulin secretagogues: old and new. Diab Rev 1999,7:139–153.

60. Langtry H, Balfour J: Glimepiride. A review of its use in the managementof type 2 diabetes mellitus. Drugs 1998, 55:563–584.

61. Dunn C, Faulds D: Nateglinide. Drugs 2000, 60:607–615.

62. Lee Y, Hirose H, Ohneda M, et al.: Beta-cell lipotoxicity in the pathogenesis of non–insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte–beta-cell relationships. Proc Natl Acad Sci USA 1994, 91:10878–10882.

63. Mudaliar S, Henry R: New oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitizers. Annu Rev Med 2001, 52:239–257.

64. Inzucchi S, Maggs D, Spollett G, et al.: Efficacy and metabolic effects ofmetformin and troglitazone in type II diabetes mellitus. N Engl J Med1998, 338:867–872.

65. Campbell L, Baker D, Campbell RK: Miglitol: assessment of its role in the treatment of patients with diabetes mellitus. Ann Pharmacother 2000, 34:1291–1301.

66. Bolli G, Di Marchi R, Park G, et al.: Insulin analogues and their potentialin the management of diabetes mellitus. Diabetologia 1999,42:1151–1167.

67. Lepore M, Pampanelli S, Fanelli C, et al.: Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000, 49:2142–2148.

68. Abraira C, Henderson W, Colwell J, et al.: Response to intensive therapysteps and glipizide dose in combination with insulin in type 2 diabetes.Diabetes Care 1998, 21:574–579.

69. Turner R, Cull C, Frighi V, et al.: Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999, 281:2005–2012.

70. Siegel E, Mayer G, Nauck M, et al.: [Factitious hypoglycemia caused by taking a sulfonylurea drug] [German]. Dtsch Med Wochenschr 1987, 112:1575–1579.

71. Wroblewski M, Gottsater A, Lindgarde F, et al.: Gender, autoantibodies,and obesity in newly diagnosed diabetic patients aged 40–75 years.Diabetes Care 1998, 21:250–255.

72. Bell G, Polonsky K: Diabetes mellitus and genetically programmed defects in b-cell function. Nature 2001, 414:788–791.

73. Kahn C: Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 1994, 43:1066–1084.

74. Kahn S:The importance of the -cell in the pathogenesis of type 2 diabetes mellitus. Am J Med 2000, 108(Suppl 6A):2S–8S.

75. Thorens B,Wu Y, Leahy J, et al.:The loss of GLUT2 expression byglucose-unresponsive beta cells of db/db mice is reversible and isinduced by the diabetic environment. J Clin Invest 1992, 90:77–85.

76. Caro J, Sinha M, Raju SM, et al.: Insulin receptor kinase in human skeletalmuscle from obese subjects with and without noninsulin-dependentdiabetes. J Clin Invest 1987, 79:1330–1337.

77. Bak J, Moller N, Schmitz O, et al.: In vivo action and muscle glycogensynthase activity in type II (noninsulin-dependent) diabetes mellitus:effects of diet treatment. Diabetologia 1992, 35:777–784.

78. McGarry J, Dobbins R: Fatty acids, lipotoxicity and insulin secretion.Diabetologia 1999, 42:128–138.

79. Unger R, Zhou Y: Lipotoxicity of beta cells in obesity and in othercauses of fatty acid spillover. Diabetes 2001, 50(Suppl 1):S118–S121.

80. Randle P, Priestman D, Mistry S, et al.: Glucose fatty acid interactions and the regulation of glucose disposal. J Cell Biochem 1994, 55S:1–11.

81. Shulman G: Cellular mechanisms of insulin resistance. J Clin Invest 2000,106:171–176.

82. Garvey W, Huecksteadt T, Matthaei S, et al.: Role of glucose transportersin the cellular insulin resistance of type II noninsulin-dependent diabetesmellitus. J Clin Invest 1988, 81:1528–1536.

83. Kelley D, Mintun M,Watkins S, et al.:The effect of non–insulin-dependentdiabetes mellitus and obesity on glucose transport and phosphorylationin skeletal muscle. J Clin Invest 1996, 97:2705–2713.

84. Cline G, Petersen K, Krssak M, et al.: Impaired glucose transport as acause of decreased insulin-stimulated muscle glycogen synthesis in type2 diabetes. N Engl J Med 1999, 341:240–246.

85. Gerich J: Metabolic abnormalities in impaired glucose tolerance.Metabolism 1997, 46:40–43.

86. Mitrakou A, Kelley D, Mokan M, et al.: Role of reduced suppression ofglucose production and diminished early insulin release in impairedglucose tolerance. N Engl J Med 1992, 326:22–29.

87. Van Haeften T, Pimenta W, Mitrakou A, et al.: Relative contributions of b-cell function and tissue insulin sensitivity to fasting and postglucose-loadglycemia. Metabolism 2000, 49:1318–1325.

88. Gerich J,Van Haeften T: Insulin resistance versus impaired insulin secretion as the genetic basis for type 2 diabetes. Curr Opin Endo Diab 1998, 5:144–148.

89. DeFronzo R:The triumvirate: B-cell, muscle, and liver: a collusion responsible for NIDDM. Diabetes 1988, 37:667–687.

90. Calles-Escandon J, Robbins D: Loss of early phase of insulin release in humans impairs glucose tolerance and blunts thermic effect of glucose. Diabetes 1987, 36:1167–1172.

91. Meyer C, Stumvoll M, Nadkarni V, et al.:Abnormal renal and hepaticglucose Metabolism in type 2 diabetes mellitus. J Clin Invest 1998,102:619–624.

92. Consoli A, Nurjhan N, Capani F, et al.: Predominant role of gluconeogenesisin increased hepatic glucose production in NIDDM. Diabetes 1989,38:550–561.

93. Magnusson I, Rothman D, Katz L, et al.: Increased rate of gluconeogenesisin type II diabetes. A 13C nuclear magnetic resonance study. J Clin Invest 1992, 90:1323–1327.

94. Nurjhan N, Consoli A, Gerich J: Increased lipolysis and its consequenceson gluconeogenesis in noninsulin-dependent diabetes mellitus. J Clin Invest 1992, 89:169–175.

95. Kelley D, Mokan M,Veneman T: Impaired postprandial glucose utilizationin non–insulin-dependent diabetes mellitus. Metabolism 1994,43:1549–1557.

96. Roden M, Petersen K, Shulman G: Nuclear magnetic resonance studies of hepatic glucose metabolism in humans. Recent Prog Horm Res 2001, 56:219–237.

97. Intensive blood-glucose control with sulphonylureas or insulincompared with conventional treatment and risk of complications inpatients with type 2 diabetes (UKPDS 33). UK Prospective DiabetesStudy (UKPDS) Group. Lancet 1998, 352:837–853.

98. Turner R:The U.K. Prospective Diabetes Study. A review. Diabetes Care1998, 21(Suppl 3):C35–C38.

99. Cusi K, DeFronzo R: Metformin: a review of its metabolic effects. Diab Rev 1998, 6:89–131.

100.Stumvoll M, Nurjhan N, Perriello G, et al.: Metabolic effects of metforminin non–insulin-dependent diabetes mellitus. N Engl J Med 1995,333:550–554.

101.Gerich J: Oral hypoglycemic agents. N Engl J Med1989, 321:1231–1245.

102.Inzucchi S: Oral antihyperglycemic therapy for type 2 diabetes: scientificreview. JAMA 2002, 287:360–372.

103.Gφke B, Herrmann-Rinke C:The evolving role of b-glucosidase inhibitors. Diabetes Metab Rev 1998, 14:S31–S38.

104.Mudaliar S, Lindberg F, Joyce M, et al.: Insulin aspart (B28 Asp-Insulin): afast-acting analog of human insulin.Absorption kinetics and action profilecompared with regular human insulin in healthy nondiabetic subjects.Diabetes Care 1999, 22:1501–1506.

105.Dimitriadis G, Gerich J: Importance of timing preprandial subcutaneousinsulin administration in the management of diabetes mellitus. Diabetes Care 1983, 6:374–377.

106.Hedman C, Lindstrom T,Arnqvist H: Direct comparison of insulin lisproand aspart shows small differences in plasma insulin profiles after subcutaneousinjection in type 1 diabetes. Diabetes Care 2001, 24:1120–1121.

107.Ratner R, Hirsch I, Neifing J, et al.: Less hypoglycemia with insulinglargine in intensive insulin therapy for type I diabetes. Diabetes Care2000, 23:639–643.

108.Rosenstock J, Schwartz S, Clark C, et al.: Basal insulin therapy in type 2diabetes. Diabetes Care 2001, 24:631–636.

 voltar